CJC-1295

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) engineered for enhanced stability and prolonged bioactivity. Its primary mechanism of action involves binding to and activating GHRH receptors on somatotroph cells of the anterior pituitary gland, triggering the pulsatile synthesis and release of endogenous growth hormone (GH).

• GHRH Receptor Activation: CJC-1295 selectively binds to GHRH receptors, initiating adenylyl cyclase activation and cyclic AMP (cAMP) production, which drives protein kinase A (PKA) phosphorylation cascades and stimulates GH gene transcription and synthesis.
• Extended Half-Life via DAC Technology: The Drug Affinity Complex (DAC) enables CJC-1295 to bind reversibly to circulating albumin after injection, dramatically extending its plasma half-life to approximately 6–8 days compared to minutes for native GHRH.
• Sustained GH and IGF-1 Elevation: By providing continuous GHRH receptor stimulation, CJC-1295 sustains elevated basal GH levels and promotes hepatic production of insulin-like growth factor-1 (IGF-1), a key mediator of anabolic and tissue repair processes.
• Preserved GH Pulsatility: Unlike exogenous GH administration, CJC-1295 preserves the natural pulsatile rhythm of GH secretion and maintains endocrine feedback loops, avoiding suppression of the body's own GH-releasing systems.

• Growth hormone secretion: CJC-1295 potently stimulates sustained GH release from the pituitary gland, with studies showing 2- to 10-fold increases in plasma GH levels persisting for up to 6 days following a single injection.
• IGF-1 elevation: Through downstream GH signalling, CJC-1295 promotes hepatic IGF-1 production, supporting cellular growth, muscle repair, and anabolic processes in research models.
• Body composition: Research in animal and human models suggests CJC-1295 may improve body composition by increasing lean muscle mass and reducing adipose tissue through elevated GH and IGF-1 activity.
• Sleep quality: As a GHRH analogue, CJC-1295 has been investigated for its potential to enhance slow-wave and restorative sleep, consistent with the established role of GHRH in sleep regulation.
• Metabolic function: Elevated GH and IGF-1 levels induced by CJC-1295 may support improved glucose metabolism, lipid utilisation, and energy expenditure in preclinical models.

Based on the available preclinical data, the most common side effects associated with CJC-1295 treatment include:

• Transient injection site reactions (redness, tenderness)
• Transient increase in heart rate (dose-dependent)
• Water retention or mild oedema
• Headache or flushing

Note: The safety profile of CJC-1295 has not been fully established, and further clinical studies are needed to fully evaluate the potential for side effects and long-term safety in mammals.

CJC-1295 is a long-acting synthetic analogue of growth hormone-releasing hormone (GHRH) that has been engineered for enhanced stability and prolonged receptor activity. Through its Drug Affinity Complex (DAC), it binds reversibly to serum albumin, extending its half-life to several days and enabling sustained stimulation of pituitary GH secretion. Research has demonstrated its ability to significantly elevate GH and IGF-1 levels while preserving the natural pulsatile secretion patterns essential for physiological hormone function. Its profile makes it a valuable research tool for studying the GH–IGF-1 axis, body composition, metabolic regulation, and the effects of sustained GHRH receptor agonism in preclinical models. Further research is ongoing to fully characterise its long-term safety and therapeutic applications.

1. Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006.
2. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006.
3. Sackmann-Sala L, et al. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. Growth Horm IGF Res. 2009.
4. Jetté L, et al. hGRF1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats. Endocrinology. 2005.
5. Van Hout A, Hearne M. Use of growth hormone releasing hormones and growth hormone releasing peptides in the elite athlete. Br J Sports Med. 2008.
6. Henninge J, et al. Identification of CJC-1295, a growth-hormone-releasing peptide, in blood samples. Drug Test Anal. 2010.
7. Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging. 2006.
8. Stanley TL, Grinspoon SK. Effects of growth hormone-releasing hormone on visceral fat, metabolic, and cardiovascular indices in human studies. Growth Horm IGF Res. 2015.

All products on this site are for research and development use only. Products are not for human consumption of any kind. The statements made on this website have not been evaluated by the US Food and Drug Administration. Neither the products described nor the company are intended to diagnose, treat, cure, or prevent any disease.